Idéal Investisseur Connexion Connexion
Français English
CAC 40 : Market closed
7 927,75 pts
-1.89%


Last updated : 20/11/2026 - 17h35
🏠 Home   ➤    Stock news

DBV Technologies Share: 1.5% Rebound After Nearly 35% Decline in Three Months

The Châtillon biotech firm regains some ground at midday, in an SBF 120 oriented upward. This rebound comes after a long series of declines, while the file submitted to the FDA at the end of September has not altered the trajectory of the share price.


DBV Technologies Share: 1.5% Rebound After Nearly 35% Decline in Three Months

A Share Still Far From Its Moving Averages

The DBV Technologies share gains 1.45% to €1.88, against €1.86 the previous day. This gain remains modest given the decline of 9.12% over one week and nearly 35% over three months. The price is trading below its 20-day moving average (€2.11, a gap of 10.76%), as well as below its 200-day moving average at €3.08, representing a gap of 38.86%.

It stands slightly above the €1.86 support level, which the share has been testing for several sessions. The RSI at 32 is close to the oversold zone, which alone does not indicate a reversal.

Short Positions Increasing Despite American Regulatory Progress

The submission of the biological license application to the FDA for the anti-peanut patch, announced on September 30, had triggered a rebound on the same day, which was erased the following day. According to the statements consulted, four funds hold 4.28% of capital in net short positions, compared to 3.64% thirty days ago, an increase of 0.64 percentage points. This rise shows that institutional investors remain positioned downward on the stock, without being able to infer their motivations.

When publishing the H1 2026 results on July 16, the company indicated sufficient cash until the third quarter of 2027, with no revenue at this stage. Its next regulatory milestone is the examination of its file by the FDA.

Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning ✓ Euronext data ✓ AI-powered analysis


Sector Pharmacie et biotechnologies › Biotechnologies


Context

Period
  • Period: 9M 2026
Key reported figures
  • Revenue: 3,1 millions de dollars
  • Quarterly revenue: 3,1 millions de dollars
  • Revenue growth: -38 %
  • Net income: -162,5 millions de dollars
  • Free cash flow: -159,4 millions de dollars
Risks mentioned
  • Substantial doubt exists about the Company's ability to continue as a going concern within twelve months
  • Manufacturing remediation activities ongoing at Fareva following FDA Warning Letter of April 2026
  • Company requires additional capital to fund operations beyond Q3 2027
Opportunities identified
  • BLA for VIASKIN Peanut Patch in children aged 4-7 years submitted with Priority Review requested, expected FDA determination in Q4 2026
  • Planned BLA submission for toddlers aged 1-3 years in 2027 with potential rolling submission approach
  • Recent $50 million ADS financing completed and $150 million ATM program refreshed to support operations and commercial readiness

The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.

Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.

Advertisement
Every morning
Technical market signals,
before the opening bell.
CAC 40 · SBF 120 · Signals · Analysts
🤖
Today's edition — pre-market
CAC 40
7 702
-0,87%
SBF 120
5 827
-0,87%
📈 Bullish signals
+5,2%
+1,8%
+0,9%
📉 Bearish signals
-14%
-5,7%
🔄 Analyst opinions
▲ 35 €
▼ 80 €
Sign up to see everything →
Before 9 AM every morning
Euronext data
AI-powered analysis





BOURSE · Chaque matin
La synthèse bourse,
avant l'ouverture.
Notre moteur analyse chaque nuit le CAC 40 et le SBF 120. Ce qui mérite attention remonte directement dans votre boîte mail. Gratuit.
✓ Avant 9h00 ✓ 1000+ inscrits ✓ 100% gratuit
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours sur les valeurs Euronext, chaque matin avant 9h.
tendance · 6 séances
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours